neurodegenerative damage after focal ischemic insult. [8] [9] [10] However, excessive autophagy may contribute to cell death. 7, 11 A recent study has indicated that autophagy plays different roles in cerebral ischemia and the subsequent reperfusion phase. 12 Thus, the contribution of autophagy to ischemic stroke needs to be reconsidered.
Pseudoginsenoside-F11 (PF11), isolated from leaves of Panax pseudoginseng subsp. Himalaicus H ARA (Himalayan Panax), is a form of ocotillol-type ginsenoside contained in Panax quinquefolium L. 13 Our studies have strongly suggested that PF11 plays an extensive role in treating many disorders of the central nervous system. For example, PF11 significantly improves AD-like cognitive impairment. 14 Also, PF11 exerts excellent antineuroinflammatory effects on LPS-activated microglia. 15 Furthermore, PF11 has a marked antagonistic effect on
Parkinson's disease. 16 Additionally, PF11 decreases morphine-induced behavioral sensitization in mice. 17, 18 Therefore, PF11, through its diverse pharmacological activities, may also have potential neuroprotective effects in the context of ischemic stroke.
Here, we focus on the effect and potential mechanisms of PF11
on the autophagic/lysosomal pathway in a rat model of pMCAO. The data show that one single administration of PF11 (3-48 mg/kg, i.v.)
significantly attenuates infarction and brain edema and improves neurological functions, even 4 hours after the onset of pMCAO, and the protective effect of PF11 may depend on restoration of autophagic flux by improving lysosomal function and autophagosome/lysosome fusion. What is more, a autophagic/lysosomal defect was detected in a rat pMCAO stroke model.
| MATERIALS AND METHODS

| Administration of drugs and chemicals
PF11 was isolated according to previously described methods. 19 The purity of PF11 detected with HPLC was more than 98%. PF11 (3, 6, 12, 24 , 48 mg/kg, i.v.) was dissolved in normal saline and administered at 0.5 hour after the onset of pMCAO by the intravenous (i.v.) route. Edaravone (5 mg/kg; China National Medicines Guorui Pharmaceutical Co., Ltd., Beijing, China) was dissolved in normal saline and administered at 0.5 hour after the onset of pMCAO 20 by the i.v.
route. Five hour before, the animals were killed, treatment with chloroquine (25 mg/kg; Sigma, St. Louis, MO, USA, C6628) was carried out by a single intracerebroventricular (i.c.v) injection with a needle (26-gauge) at the following stereotaxic coordinates: 0.8 mm anterior to the bregma, 1.5 mm lateral to the midline, and 3.6 mm ventral to the skull surface. 21 
| Animals and pMCAO rat model
Male Sprague-Dawley (SD) rats weighing 270-300 g (age 8 weeks ap- 
| Measurement of cerebral infarct volume, cerebral edema, and neurological function
Rats were killed at 0 hour (sham-operated rats, sham) or 24 hours postpMCAO, and their brains were quickly removed, weighed accurately, and then sliced into six coronal sections, each of 2 mm thickness. The slices were incubated in a 1% solution of TTC (Sigma, T8877) at 37°C for 20 minutes, and then photographic images were taken. Afterward the slices were dried at 100°C for 24 hours and then weighed accurately. The brain water content was determined as an indicator of cerebral edema using a wet/dry method as previously described. 23 The cross-sectional areas, with or without infarction, in each brain slice were measured using Image J analysis software (version 1.6, National
Institutes of Health, Bethesda, MD, USA). The total mean infarct area of each section was examined by the change in coloration. 24 Neurological function was evaluated with the modified Neurological Severity Score (mNSS) test. 25 Each function is graded on a scale of 0-18 (normal score, 0; maximal deficit score, 18). Higher scores indicate more severe behavioral deficits. The mNSS test was performed in the saline-and PF11-treated rats at 24 hours after the pMCAO procedure.
| Fluoro-Jade B staining
Staining was performed according to the manufacturer's protocol (Histo-Chem Inc., Jefferson, AR, 2FJB). Sections were dried on slides at 50°C for 30 minutes, immersed in a solution containing 1% sodium hydroxide in 80% alcohol, followed by 2 minutes in 70% alcohol and 2 minutes in distilled water. Slides were transferred to a solution of 0.06% potassium permanganate for 10 minutes on a shaker table and, then, washed in distilled water. After 20 minutes in Fluoro-Jade B staining solution, the slides were rinsed for 1 minute in each of three distilled water washes and, then, placed on a slide warmer at 50°C in the dark until they were completely dry. Sections were cleared by immersion in xylene for 1 minute before cover slipping with DPX (Sigma, 317616).
| Immunoblotting
At 24 hours after pMCAO, brain tissues from the ischemic cortex and the corresponding area of sham-operated rats were rigorously homogenized in RIPA buffer. An aliquot of 25 μg-30 μg of total protein from each sample was separated using 10%-12% SDS-polyacrylamide gel electrophoresis using constant current. Proteins were subsequently transferred to nitrocellulose membrane or polyvinylidene fluoride membrane, which were subsequently incubated with 5% skimmed milk. 
| Immunofluorescence
Rats were perfused with PBS (pH 7.4) followed by 4% paraformalde- 
| TUNEL staining
To identify the apoptosis rate in cells expressing LC3, double staining of LC3 and the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) were performed. Immunofluorescence staining of LC3 was performed according to the above procedure.
TUNEL staining was applied using an in situ Cell Death Detection Kit (Roche, Basel, Switzerland, 11684795910). Staining was performed according to the manufacturer's protocol.
| Statistical analysis
Statistical analysis was carried out using SPSS 19.0 software for Windows (SPSS Inc, Chicago, IL, USA). Western blot and immunofluorescence results were analyzed with one-way analysis of variance (ANOVA), followed by Tukey's test. Data are expressed as means±SEM. Infarct area and brain water content data are expressed as mean±SEM and were statistically analyzed using one-way ANOVA followed by Bonferroni's post hoc test. mNSS scores are expressed as the mean±SEM and were analyzed with Kruskal-Wallis one-way ANOVA on ranks, followed by Dunn's method. P<.05 was considered statistically significant.
| RESULTS
| PF11 reduced the infarct volume and brain water content, and improved the behavioral outcome
The results showed that one single treatment of PF11 (3, 
| PF11 rescued pMCAO-induced neural cell death and glial cell activation
As shown in Figure 2A , in pMCAO-treated rats, many neurons (identified by labeling with NeuN) were damaged as evidenced by irregularly aligned and shrunken somata, and this was accompanied by a sham-operated cortex, more GFAP-reactive astrocytes were seen at 24 hours following pMCAO. 27, 28 PF11 reversed the abnormal astrocyte activation induced by ischemic insult ( Figure 2C ). To measure the extent of neuronal degeneration in the pMCAO rats, neurons were stained with Fluoro-Jade B (FJB). As shown in Figure 2D , few dying F I G U R E 1 PF11 reduces infarct volume and brain water content and improves behavioral outcome after pMCAO. (A, B) Effect of PF11 on the cerebral infarct volume, examined by 2,3,5-triphenyltetrazolium chloride staining of serial coronal brain sections at 24 h after pMCAO. PF11 (3, 6, 12, 24, 48 mg/kg) and edaravone (5 mg/kg) were administered (i.v.) at 0.5 h after the onset of pMCAO. The neuroprotective agent edaravone (Eda) was used as a positive control. Statistical analysis was performed with one-way ANOVA, followed by the Bonferroni's test (the same statistical tests were used for C, E and F). Data are presented as mean±SEM from 8 to 10 rats/group (the same number in C and D Figure 2F ). 
| PF11 attenuated pMCAO-induced accumulations of autophagosomes and apoptosis
| PF11 attenuated the pMCAO-induced accumulations of autophagosomes and autophagic substrates
Although mounting evidence has suggested the existence of autophagy in ischemic stroke, 7, 11, 12, 30 the functions of autophagy in this process remain unclear. To address this question, we conducted immunoblot analyses using a panel of autophagic pathway markers that allowed us to interrogate multiple steps in the autophagic pathway and the potential effect of PF11. As shown in Figure 4A and B, a dramatic enhancement in the ratio of LC3-II/β-actin was observed in the rat cortex region at 24 hours following pMCAO, which was in accordance with previous studies in multiple ischemic stroke models. 7, 12, 21 Expression of SQSTM1, a well-known autophagic substrate also named p62, 31 was slightly but not significantly decreased by pMCAO ( Figure 4A and C). This suggested an abnormal accumulation of protein substrate, in contrast to the majority of previous studies which showed that SQSTM1 is significantly decreased following ischemic stroke insult. 12 Meanwhile, in response to ischemic insult, a To further investigate this, we analyzed the upstream mTOR signaling pathway, a well-known regulator of autophagy. 32 We used immunoblotting to examine the phosphorylation status of mTOR and its substrate, p70S6K. The data showed no significant difference in the p-mTOR/t-mTOR ratio or the p-p70S6K/t-p70S6K ratio 24 hours after pMCAO ( Fig. S1A and 1B) , suggesting that the accumulation of autophagosomes was independent of the mTOR/ p70S6K pathway.
| PF11 attenuated pMCAO-induced lysosome dysfunction and defective autophagosome/ lysosome fusion
To further substantiate whether pMCAO induces autophagosome accumulation by increasing the formation or decreasing the degradation of autophagosomes, we investigated the function of lysosomes, which are responsible for the digestion of autophagic substrates. Western blot analysis of cortex extracts showed that expression of lysosomeassociated membrane protein-2 (LAMP2) and the mature lysosomal protease cathepsin B was significantly decreased at 24 hours following pMCAO ( Figure 5B-D) . We also assessed lysosomal function by using confocal microscopy to examine the colocalization of the lysosomal F I G U R E 2 PF11 rescues pMCAO-induced neural cell death and glial cell activation. Immunofluorescence images showing that PF11 significantly reversed the pMCAO-induced neuron death (A), microglial activation (B), and astrocyte activation (C) in the ipsilateral cortex, as detected by laser confocal microscopy using antibodies against NeuN (red), Iba-1 (green), and GFAP (green), respectively. Fluoro-Jade B (FJB) staining was used to identify degenerating neuronal cells (D, green). Scale bar=20 μm. (E, F) Statistical analysis of surviving neurons (NeuNpositive) and degenerating neurons (FJB-positive) was conducted using Image-Pro Plus 6.0. The values are presented as means±SEM (n=18). Statistical comparisons were carried out with ANOVA followed by Tukey's test. ###P<.001 vs sham group, ***P<.001 vs pMCAO group. pMCAO denotes rats subjected to pMCAO for 24 h; pMCAO+PF11 (3, 6, 12 mg/kg, iv) denotes rats that were injected with PF11 at 0.5 h after the onset of pMCAO. Rats were perfused with 4% paraformaldehyde, and 20 μm brain cortex sections were processed for immunofluorescence examination. (G) The black ovals indicate the regions selected for immunofluorescence detection markers LAMP2 and cathepsin B (see high-magnification images in the right panels of Figure 5A ). Consistent with the immunoblotting results, immunofluorescence analysis of LAMP2 and cathepsin B in cortical cells revealed that the signals from both proteins were strongly reduced by pMCAO, which is suggestive of marked lysosomal dysfunction ( Figure 5A ). Moreover, the expression of V-ATPase, a proton pump that establishes and maintains the acidic environment of lysosomes, 33 was significantly decreased as determined by immunoblotting ( Figure 5B and E). A significant decline in the level of VAMP7, a member of the SNARE complex which is responsible for the fusion of lysosomes with autophagosomes, 34 was also observed, suggesting that the fusion process may be affected by ischemic insult ( Figure 5B and F). All these data suggested that there was a selective impairment in lysosome function and autophagosome/lysosome fusion following pMCAO.
Next, the effect of PF11 (3, 6, 12 mg/kg) on lysosomal function was examined. The data showed that PF11 markedly increased the LAMP2 and V-ATPase levels after the challenge by pMCAO. Similarly, confocal analysis showed that PF11 dramatically increased the expression and colocalization of LAMP2 and CatB in a dose-dependent manner ( Figure 5A ). PF11 also partly reversed the ischemia-induced decline in VAMP7, as judged by immunoblotting ( Figure 5F ). These data suggested that PF11 was capable of improving lysosomal func- Moreover, PF11 (12 mg/kg) significantly reduced the abundance of autophagosomes as compared with the ischemia group, and this decrease was reversed by CQ ( Figure 5G and H). The variation in the levels of SQSTM1 and LAMP2 was shown in Figure 5G , I, and J. These results strongly indicated that treatment with a high concentration of PF11 can restore the autophagic flux by improving lysosomal function.
| The protective effect of PF11 on ischemic stroke was abolished by chloroquine (CQ)
To further clarify whether the protective effect of PF11 on ischemic insult was dependent on alleviating the autophagic/lysosomal defects, we investigated the ischemic stroke outcome and the apoptosis- expression as compared to the pMCAO group, and this change was markedly reversed by CQ (25 mg/kg) ( Figure 6A-C) . Also, the TTC staining, brain water content, and neurological scores indicated that the protective effect of PF11 on permanent ischemic insult was abolished by CQ (Figure 6D-G) . Additionally, confocal analysis showed that PF11 increased the expression of NeuN ( Figure 6H ) and decreased the colocalization of TUNEL and LC3 ( Figure 6I ) following ischemic insult, and these changes were reversed by CQ (right panels of Figure 6H and I). These results strongly indicated that the protective effect of PF11 against ischemic stroke may depend on alleviating autophagic/lysosomal defects. There is no strict parallel relationship between infarct volume and neurological scores. 36 Although TTC staining allowed us to delineate clearly the boundaries of the necrotic tissues, this staining did not allow fine evaluation of the morphological status of the dying or intact neurons. 36 Thus, it is possible that the high dose of PF11 (48 mg/kg) had a protective effect on dying or intact neurons, leading to a significant improvement in neurological function, but had little effect on necrotic neurons, so that no significant changes were found in infarct volume. Furthermore, it is particularly noteworthy that PF11 (12 mg/ kg) exhibited significant neuroprotection. In addition, these findings indicate that the autophagic flux is impaired in a rat model of pMCAO.
Our findings suggest a potential therapeutic role for PF11.
It is well known that apoptosis and necrosis contribute to the development of ischemia-induced delayed cell death. 37 In recent years, it has been shown that autophagic cell death, which is distinct from apoptosis and is also called type II programmed cell death, 38 is involved in cerebral ischemia-mediated cell death. 29, 39, 40 Our data also showed that dying cells displayed large-scale accumulation of autophagosomes following ischemic insult, which was reversed by PF11 at a dose of 12 mg/kg. These results support the idea that PF11 protects against cell death and has a potential relationship with autophagy.
Mounting evidence has suggested that the autophagic flux is stimulated, and autophagosomes accumulate in several models of ischemic stroke. 7, 12 In the present study, the level of LC3-II also strongly increased following pMCAO. Interestingly, in our study, the levels of the autophagic substrate SQSTM1 did not significantly decrease 24 hours after ischemic insult, a result which differed from other experimental stroke models. 8, 12 However, in the latest study, using human postmortem tissue, increased expression of SQSTM1 was observed, suggesting an accumulation of autophagic substrates after human stroke. 30 This increased level of SQSTM1 may be indicative of inhibition of lysosomal function. Furthermore, the increased oxidative stress that is known to occur in stroke is also associated with increased levels of SQSTM1.
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In addition, caspase-8, which is activated after cerebral ischemic insult, recruits SQSTM1 to further regulate caspase-8 activation. 42 In a recent study, it was reported that self-oligomerization of SQSTM1 is responsible for its localization to the autophagosome formation site, which is associated with the endoplasmic reticulum (ER), and this process occurs independently of LC3. 43 Thus, there is not necessarily an inverse correlation between LC3 and SQSTM1. However, the detection of SQSTM1 levels alone is not sufficient to confirm autophagic removal, and for this reason, the level of polyubiquitinated protein aggregates has often been determined to confirm the efficiency of autophagic clearance in multiple diseases. 44 Our data showed that ubiquitin levels tended to increase following ischemic insult, suggesting a low rate of autophagic clearance. Furthermore, PF11 reversed the accumulation of autophagic substrates, suggesting a high efficiency of autophagic clearance.
Because autophagosomes fuse with and are then degraded by lysosomes, the accumulation of autophagosomes or LC3-II protein after brain ischemia can be due to either increased formation or decreased lysosomal degradation of autophagosomes. Therefore, we examined the steps involved in both the formation and degradation of autophagosomes following ischemic stroke. Our data showed that no significant change was detected in the expression of p-mTOR and p-p70S6K as compared to the sham group (Fig. S1A-C) , suggesting that the accumulation of autophagosomes was independent of the mTOR/p70S6K pathway. Next, we investigated whether lysosomal dysfunction and defective autophagosome/lysosome fusion could be detected following ischemic insult. Up to now, the function of lysosomes following ischemic stroke is still an area of widespread controversy. Although in some studies lysosomes and lysosomal hydrolases are activated to remove autophagic aggregates after ischemic stroke, 7 it is noteworthy that ischemic injury can trigger cytosolic acidification and rupture/permeabilization of lysosomes, thereby leading to cathepsin-mediated cell death. 45, 46 We observed that PF11 had remarkable effects in reversing pMCAO-mediated lysosomal dysfunction. Thus, we supposed that PF11 reduced the accumulation of autophagosomes and autophagic substrates by improving lysosomal function and accelerating autophagosome/ lysosome fusion. To further confirm this hypothesis, a lysosomal inhibitor CQ was used to test the reason of accumulation of autophagosomes after brain ischemia, as judged by assaying the level of the autophagosomal marker protein LC3-II. 35 The results showed that the influence of PF11 on the abundance of autophagosomes and lysosomal dysfunction induced by pMCAO could be reduced by CQ to a level similar to that in the pMCAO group. Thus, PF11 had a relatively selective effect in reversing the pMCAO-driven accumula- Lysosomal dysfunction has been viewed as a pathogenic factor in several neurodegenerative diseases 47, 48 and myocardial ischemia 49 and is also a potential therapeutic target. It is now accepted that the magnitude of lysosomal rupture may influence the rate of cell death. 50 However, the detailed mechanisms underlying lysosomal destabilization still remain poorly understood. Heat-shock protein-70 (HSP70) is known to stabilize lysosomal membranes and protect cells from oxidative stress and apoptotic stimuli. 51 Interestingly, in the present study, the expression of HSP70 was significantly decreased after ischemic stroke, and PF11 could reverse this effect (Fig. S2A-B) , suggesting that the favorable effect of PF11 on lysosomes might be related to enhancement of the HSP70 protein level.
In conclusion, we have shown that the autophagic flux is impaired, and PF11 exerts an excellent protective effect by alleviating autophagic/lysosomal defects in a rat ischemic stroke model.
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